Foghorn Therapeutics Inc. (FHTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Adrian H. B. Gottschalk | President, CEO & Director | 784.65k | -- | 1976 |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer | 572.6k | -- | 1965 |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer | 300.16k | -- | 1972 |
| Dr. Gerald R. Crabtree M.d. | Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Kristian Humer M.B.A. | Chief Financial Officer | -- | -- | 1976 |
| Ms. Karin Hellsvik | VP, Corporate Affairs & Investor Relations | -- | -- | -- |
| Mr. Michael J. LaCascia | Chief Legal Officer | 565.5k | -- | 1965 |
| Mr. Saurabh Sewak Ph.D. | Vice President of Corporate Development | -- | -- | -- |
| Mr. Carlos Costa | Chief People Officer | -- | -- | 1974 |
| Ms. Fanny Cavalie | Chief Strategy & Business Operations Officer | -- | -- | 1978 |
Foghorn Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 116
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Recent Events
- Apr 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 09, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 07, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing